Designs and Models in Drug Development
Monday 2 June, 2:40--4:30

Moderator: Alfred BARRON
Johnson \& Johnson

PA2 Estimation: Alternative Designs/Models

Krishnendu GHOSH
Wyeth-Ayerst Research, Princeton, NJ, USA
The potencies of pharmacological competitive antagonists are commonly expressed in terms of PA2 values (negative of log of antagonist concentration corresponding to a dose-ratio of 2). Commonly used estimation method for PA2 is Schild's method. This method does not utilize the variabilities in the ED50s in calculating the PA2. Alternative design and model was suggested by Lazareno and Birdsall. This method requires much less experimental units and use both the agonist and antagonist concentrations simultaneously. Both the methods assume that the antagonist administered alone (in the absence of the agonist) has no effect. Many recent studies show that antagonist administered alone may have a dose-response relationship. In such situations we have shown that both the above methods will fail to provide appropriate PA2 estimates and indicate that the antagonists are non-competitive. We have derived alternative designs and models for estimating PA2, Kd, and IC50 for the antagonist in such situations.

[Krishnendu Ghosh, Biometrics Research, Wyeth-Ayerst Research, ghoshk@war.wyeth.com]


Assessing the Superiority of a Combination Drug from a Bayesian Perspective

Paulette CEESAY, Sanat K. SARKAR
Temple University, Philadelphia, PA, USA
Steve SNAPINN
Merck Research Laboratories, Blue Bell, PA, USA
Many researchers have studied the problem of testing the superiority of a combination of two drugs to its components using frequentist methodologies. However, the frequentist approach is complicated by the presence of the nuisance parameter measuring the mean difference between components, and this can lead to low power. By using a prior that reflects one's knowledge about the component drugs, we provide a formal Bayesian approach for studying several fixed-dose combinations of two drugs witn unknown variance where the design of the experiment is a multilevel factorial clinical trial in order to determine if at least one provides a more effective treatment than its components. This approach avoids the problem of dealing with the nuisance parameter, and is better at detecting the superiority of a combination when the gains over its respective components are moderate. The Bayesian procedure could be especially useful in Phase II clinical trials.

[Paulette Ceesay, Temple University, Department of Statistics, Phila., PA 19122, USA, paulette@vm.temple.edu]


Use of Sequential Simplex Design for Optimization Based on Sensory Evaluation

George ZELIGER
Trilogy Consulting Corp., Princeton, NJ, USA and Anvical-Simplex, Boston, MA, USA
A modification of the Sequential Simplex Design originally proposed by Spendley, Hext, and Himsworth is presented. The technique is aimed to the situation where it is easier to recognize the best outcome of those obtained in vertices of a regular simplex in the factor space, rather than the worst one as it is in the original approach. The situation embraces cases of sensory as well as of multidimensional evaluation of the optimization criterion, e.g., quality of a product or performance of a process. Formulae for simplex rotation are given, stopping rules and approaches to dealing with constraints are discussed. Use of sorting algorithms well known in Computer Science is proposed for finding the pivotal vertex of the simplex. (The proposal has some application value of its own.) Convergence of the process is briefly discussed, results of numerical experiments and comparison with other methods are reported. As a by-product of the approach, the opportunity to run parallel experiments or calculations is stated that allows to reduce the total experimental time nearly proportionally to the number of the parameters of the problem compared to the original approach. In other words, it becomes possible to treat any multiparametric optimization problem as one-dimensional. Potential applications of the approach range from experimental design in drug, food, and cosmetics development to car manufacturing to architectural acoustic design.

[George Zeliger, 1725 Commonwealth Ave., Apt. 2, Brighton, MA, 02135, gzeliger@genetics.com]


Back to JRC program
Back to JRC Home Page